Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Rev. urug. cardiol ; 37(1): e706, jun. 2022. ilus
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1415403

ABSTRACT

El término miocarditis hace referencia a una inflamación del miocardio, que puede tener diversas causas (infecciones, tóxicos, enfermedades autoinmunes). Su diagnóstico es desafiante debido al gran espectro de presentaciones clínicas que puede adoptar, muchas veces imitando patologías más prevalentes como el infarto agudo de miocardio. La miocarditis asociada a enfermedades autoinmunes es poco frecuente, y la importancia de reconocerla radica en que el diagnóstico e inicio temprano del tratamiento son cruciales para mejorar su pronóstico. Presentamos aquí un caso clínico de una perimiocarditis lúpica.


Myocarditis refers to an inflammation of the myocardium, which can have various causes (infections, toxic substances, autoimmune diseases). Its diagnosis is challenging due to the wide spectrum of clinical presentations, often mimicking more prevalent pathologies such as acute myocardial infarction. Myocarditis associated with autoimmune diseases is rare, and the importance of recognizing is that early diagnosis and initiation of treatment are crucial to improve its prognosis. We present here a clinical case of lupus perimyocarditis.


O termo miocardite refere-se a uma inflamação do miocárdio, que pode ter várias causas (infecções, substâncias tóxicas, doenças autoimunes). Seu diagnóstico é desafiador devido ao amplo espectro de apresentações clínicas que pode ter, muitas vezes mimetizando patologias mais prevalentes como o infarto agudo do miocárdio. A miocardite associada a doenças autoimunes é rara, e a importância de reconhecê-la reside no fato de que o diagnóstico precoce e o início do tratamento são cruciais para melhorar seu prognóstico. Apresentamos aqui um caso clínico de perimiocardite lúpica.


Subject(s)
Humans , Female , Adult , Heart Failure/therapy , Myocarditis/diagnostic imaging , Chest Pain , Methylprednisolone/therapeutic use , Treatment Outcome , Immunoglobulins, Intravenous/therapeutic use , Cyclophosphamide/therapeutic use , Hydroxychloroquine/therapeutic use , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/complications , Myocarditis/etiology , Myocarditis/drug therapy
2.
China Journal of Chinese Materia Medica ; (24): 829-835, 2022.
Article in Chinese | WPRIM | ID: wpr-927966

ABSTRACT

To evaluate the pharmacoeconomic value of Qidong Yixin Oral Liquid in the treatment of viral myocarditis(Qi-Yin deficiency syndrome) by supplementing Qi, nourishing the heart, calming the mind, and relieving palpitation, the present study performed the Meta-analysis based on the published papers on Qidong Yixin Oral Liquid by AMSTAR and carried out pharmacoeconomic evaluation using TreeAge Pro by the cost-effectiveness analysis. The results showed that the quality of the included papers was good. After four weeks of treatment, Qidong Yixin Oral Liquid combined with the conventional treatment regimen was superior to the conventional treatment in improving creatine kinase isoenzyme, and the difference was statistically significant. Furthermore, the treatment cost was also higher than that of conventional treatment, with an incremental cost-effectiveness ratio of CNY 95.89, accounting for 0.30% of per capita disposable income. The results of sensitivity analysis showed that the research results were robust. Therefore, based on the assumption that the per capita disposable income in 2020 was the threshold of patients' willingness to pay, it is more economical for patients with viral myocarditis to use Qidong Yixin Oral Liquid combined with conventional secondary prevention regimen than conventio-nal secondary prevention regimen alone. The economic evaluation of Qidong Yixin Oral Liquid in the treatment of viral myocarditis will help physicians and patients choose optimal treatment options, improve rational clinical medication, and provide references for the efficient allocation and utilization of medical resources in China.


Subject(s)
Humans , Cost-Benefit Analysis , Drugs, Chinese Herbal/therapeutic use , Economics, Pharmaceutical , Myocarditis/drug therapy , Qi , Yin Deficiency/drug therapy
5.
Clin. biomed. res ; 37(1): 51-54, 2017. ilus
Article in Portuguese | LILACS | ID: biblio-833304

ABSTRACT

A miocardite é cada vez mais diagnosticada, principalmente pela maior disponibilidade de métodos como a ressonância magnética cardíaca. A apresentação clínica é variável, geralmente posterior a uma infecção respiratória ou gastrointestinal, manifestando-se como síndrome coronariana aguda (SCA), insuficiência cardíaca aguda ou crônica, arritmias cardíacas ou mesmo choque cardiogênico inexplicável. Relatos de casos de miocardite após infecção do trato urinário (ITU) são escassos. Neste relato, descrevemos o caso de um paciente masculino de 24 anos com miocardite após ITU que se apresentou sob a forma de SCA(AU)


The diagnosis of myocarditis has increased mainly due to greater availability of methods such as cardiac magnetic resonance (CMR). Its clinical presentation varies, usually following respiratory or gastrointestinal tract infection, in patients presenting with acute coronary syndrome (ACS), acute or chronic heart failure, cardiac arrhythmias, or even unexplained cardiogenic shock. Case reports of patients with myocarditis following urinary tract infection (UTI) are scarce. This is a case report of a 24-year-old male patient with myocarditis with symptoms of ACS following UTI(AU)


Subject(s)
Humans , Male , Adult , Acute Coronary Syndrome/diagnosis , Myocarditis/diagnosis , Myocarditis/drug therapy , Myocarditis/etiology , Urinary Tract Infections/complications , Diagnosis, Differential
7.
Rev. Soc. Bras. Med. Trop ; 47(5): 663-665, Sep-Oct/2014. graf
Article in English | LILACS | ID: lil-728900

ABSTRACT

Although malaria is one of the oldest types of parasitic infection, we have recently witnessed substantial changes in the outcome of malarial infections. Severe Plasmodium vivax infections have recently become more frequent, and are occasionally associated with fatal outcomes. Cardiac arrhythmia and myocardial failure have also been reported, typically in association with Plasmodium falciparum infections. We report a case of myocarditis and heart failure, due to Plasmodium vivax infection, along with the favorable outcome.


Subject(s)
Humans , Male , Young Adult , Heart Failure/parasitology , Malaria, Vivax/complications , Myocarditis/parasitology , Heart Failure/drug therapy , Malaria, Vivax/drug therapy , Myocarditis/drug therapy , Treatment Outcome
9.
Mem. Inst. Oswaldo Cruz ; 107(4): 513-521, June 2012. ilus, graf
Article in English | LILACS | ID: lil-626446

ABSTRACT

Trypanosoma cruzi infection induces progressive cardiac inflammation that leads to fibrosis and modifications in the heart architecture and functionality. Statins, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been studied due to their pleiotropic roles in modulating the inflammatory response. Our goal was to evaluate the effects of simvastatin on the cardiac inflammatory process using a cardiotropic strain of T. cruzi in a murine model of Chagas cardiomyopathy. C57BL/6 mice were infected with 500 trypomastigotes of the Colombian strain of T. cruzi and treated with an oral dose of simvastatin (20 mg/Kg/day) for one month and inflammatory and morphometric parameters were subsequently evaluated in the serum and in the heart, respectively. Simvastatin reduced the total cholesterol and inflammatory mediators (interferon-gamma, tumour necrosis factor-alpha, CCL2 and CCL5) in the serum and in the heart tissue at 30 days post-infection. Additionally, a proportional reduction in heart weight and inflammatory infiltration was observed. Simvastatin also reduced epimastigote proliferation in a dose-dependent manner in vitro and was able to reduce blood trypomastigotes and heart amastigote nests during the acute phase of Chagas disease in vivo. Based on these data, we conclude that simvastatin exerts a modulatory effect on the inflammatory mediators that are elicited by the Colombian strain of T. cruzi and ameliorates the heart damage that is observed in a murine model of Chagas disease.


Subject(s)
Animals , Male , Mice , Chagas Cardiomyopathy/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Myocarditis/drug therapy , Simvastatin/administration & dosage , Acute Disease , Chagas Cardiomyopathy/pathology , Disease Models, Animal , Fibrosis , Inflammation Mediators/blood , Interferon-gamma/blood , Myocarditis/blood , Time Factors , Tumor Necrosis Factor-alpha/blood
10.
Rev. bras. cir. cardiovasc ; 25(2): 149-153, abr.-jun. 2010. ilus
Article in English | LILACS | ID: lil-555858

ABSTRACT

OBJECTIVE: Cytomegalovirus (CMV) systemic disease and myocarditis in healthy persons is infrequently reported in the literature, although in increasing numbers in recent years. The importance of the recognition of the syndrome that usually has an initial picture of a mononucleosis like infection in an otherwise healthy person, is the available therapeutic agent, ganciclovir, that can cure the infectious disease. METHODS: We analyzed the clinical result of pulsotherapy with steroids in a patient with CMV myocarditis after 7 days of etiological treatment, with ganciclovir, intravenous vasodilators, and the conventional treatment for congestive heart failure. RESULTS: The clinical condition of the patient improved accordingly to the better function of the left ventricle, and the ganciclovir was kept for 21 days, most of it in an out patient basis. The patient was dismissed from the hospital, with normal myocardial function. CONCLUSION: Potentially curable forms of myocarditis, like M pneumoniae and CMV, for example, can have an initial disproportionate aggression to the myocardium, by the acute inflammatory reaction, that can by itself make worse the damage to the LV function. In our opinion, the blockade of this process by pulsotherapy with steroids can help in the treatment of these patients. We understand that the different scenario of immunosuppressive treatments for the possible auto immunity of the more chronic forms of the presumably post viral cardiomyopathy has been in dispute in the literature, and has stolen the focus from the truly acute cases.


OBJETIVO: Doença sistêmica por citomegalovírus (CMV) com miocardite em pessoas saudáveis é raramente referida na literatura, apesar de em maior número em anos recentes. A importância do reconhecimento da síndrome, que usualmente tem um quadro inicial "mononucleosis like" em uma pessoa sadia é a disponibilidade do agente terapêutico ganciclovir, que pode curar a infecção. MÉTODOS: Nós analisamos o resultado da pulsoterapia com esteróides em um paciente com miocardite por CMV, após 7 dias de tratamento etiológico com ganciclovir, vasodilatadores intravenosos e o tratamento convencional para insuficiência cardíaca congestiva. RESULTADOS: A condição clínica do paciente melhorou com a melhor função do ventrículo esquerdo e o ganciclovir foi mantido por 21 dias após alta hospitalar.A função miocárdica retornou ao normal. CONCLUSÃO: Formas curáveis de miocardites como M pneumonia e CMV, por exemplo, podem ter uma agressão grave ao miocárdio por uma ação inflamatória que pode piorar a função cardíaca. Em nossa opinião, o bloqueio deste processo pela pulsoterapia com esteróides pode auxiliar no tratamento destes pacientes. Entendemos que existe um cenário diferente de tratamento com imunossupressores para possível agressão auto-imune das formas mais crônicas de cardiomiopatias dilatadas e isso está em disputa na literatura, talvez mudando o foco dos casos realmente agudos.


Subject(s)
Adult , Humans , Male , Cytomegalovirus Infections/drug therapy , Myocarditis/drug therapy , Shock, Cardiogenic/drug therapy , Anti-Bacterial Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Antiviral Agents/therapeutic use , Ganciclovir/therapeutic use , Glucocorticoids/therapeutic use , Injections, Intravenous , Myocarditis/virology , Prednisone/therapeutic use , Shock, Cardiogenic/etiology , Teicoplanin/therapeutic use
11.
Mem. Inst. Oswaldo Cruz ; 104(7): 1023-1030, Nov. 2009. tab, ilus
Article in English | LILACS | ID: lil-534170

ABSTRACT

We investigated whether sequestered Trypanosoma cruzi antigens found in heart interstitial dendritic cells (IDCs) contribute to the residual myocarditis found in mice following treatment with benznidazole, a specific chemotherapeutic drug. IDCs are antigen-presenting cells that are MHC-II-receptor dependent. Swiss mice were divided into two experimental groups: the 1st group was infected with the Colombian strain of T. cruzi, which is resistant to treatment with benznidazole, and the 2nd group was infected with clone 21SF-C 3, which has a medium susceptibility to the drug. Treatment of the Colombian strain group started on the 120th day post-infection and for the 21SF-C3 strain group treatment was started on the 90th day. In both groups, treatment lasted for 90 days. The animals were sacrificed either 150 or 200 days post-treatment. The myocardium was analysed by immunohistochemistry using anti-MAC3, 33D1, CD11b and CD11c monoclonal antibodies for IDCs or anti-T. cruzi purified antibodies. Parasite antigens were expressed on the IDC membranes in both treated and untreated mice. Myocarditis subsided following treatment, evidenced by both histological and morphometrical evaluation. A reduction in the number of IDCs carrying T. cruzi antigens in the treated group indicates that the elimination of parasites influences antigen presentation with concomitant decreases in inflammation. There is a correlation between the presence of T. cruzi antigens in these cells and the chronic focal, residual myocarditis seen in treated mice.


Subject(s)
Animals , Mice , Antigens, Protozoan/analysis , Chagas Cardiomyopathy/immunology , Dendritic Cells/immunology , Myocarditis/immunology , Myocardium/cytology , Trypanosoma cruzi/immunology , Antibodies, Monoclonal/blood , Antigens, Protozoan/drug effects , Chagas Cardiomyopathy/drug therapy , Chagas Cardiomyopathy/pathology , Disease Models, Animal , Drug Resistance , Dendritic Cells/pathology , Myocarditis/drug therapy , Myocarditis/pathology , Myocardium/immunology , Nitroimidazoles/therapeutic use , Time Factors , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/classification
13.
Heart Views. 2008; 9 (4): 137-141
in English | IMEMR | ID: emr-102822

ABSTRACT

The optimum treatment for acute viral myocarditis in pediatric population is unknown. Some studies have shown the beneficial effect of high dose intravenous immunoglobulin [IVIG] while other reports suggested the corticosteroid to be effective in the treatment of acute viral myocarditis. In this study, we present our experience with combined use of high dose IVIG and corticosteroid along with conventional antifailure treatment for clinical acute viral mypcarditis in pediatric population. Thirteen patients were included in the study with the clinical diagnosis of acute viral myocardistis and reduced cardiac function ie fractional shortening of < 28%. In the study group, 53% were male and 46% female with median age of 12 months and were treated with high dose IVIG and corticosteroid. Left ventricular function, left ventricular end diastolic dimension [LVEDD] and degree of mitral regurgitation [MR] were assessed echocardiographically at presentation; at 6 weeks and then at 6 months follow-up. At 6 months follow-up, LV function normalized in 92% of the patients, LVEDD improved in 62% and 84.6% of the patients had insignificant MR. Our data suggest that use of high dose IVIG in combination with corticosteroid is an effective treatment for acute viral myocarditis in pediatric population


Subject(s)
Humans , Male , Female , Immunoglobulins, Intravenous , Steroids , Child , Ventricular Function, Left , Stroke Volume , Echocardiography , Myocarditis/drug therapy
14.
Arch. cardiol. Méx ; 75(supl.3): 81-88, jul.-sep. 2005. tab
Article in Spanish | LILACS | ID: lil-631926

ABSTRACT

La miocarditis aguda (MA) se asocia a infecciones virales: Coxsackie B, ECHOvirus y otros. Mecanismos autoinmunes se suponen patogénicos. La clínica es variable. El beneficio de inmunosupresión clásica (prednisona-azatioprina) o inmunomodulación (IgG-monomérica) no ha sido confirmado. Objetivo: Revisar la incidencia y enfoque de estudio de la miocarditis. Material y métodos: De 1992-2003, aplicamos un cuestionario estándar a 49 pacientes consecutivos con diagnóstico establecido en forma independiente. Se excluyeron MA con causa identificable. Resultados: La MA ocurrió en 17 mujeres y 32 hombres, edad (mediana) 24 y 28 años. Predominaron disnea/ortopnea (70-47%), edema/plétora yugular (41-37%), dolor precordial y taquicardia (50%). En 22 (45%) la clase funcional era III-IV. El electrocardiograma mostró taquicardia sinusal (35%) y bloqueos de rama (24%). En 47 pacientes el ecocardiograma mostró FEVI 41% (promedio), DDVI 53 mm (promedio) y discinesia 89%. En 11 (22%) casos investigamos anticuerpos contra Coxsackie/ECHOvirus, 6 (54%) tenían anticuerpo reconocido. Veintinueve casos (61%) progresaron a miocardiopatía dilatada (MD), hubo tres defunciones (6%). No fue posible valorar tratamiento inmunomodulador, se estudió sólo a 12 casos. Conclusiones: La incidencia de MAes 1/1,000 ingresos/año. Es necesario estandarizar manejo diagnóstico y tratamiento, pues la progresión a MD y/o muerte en etapa aguda ocurre en 2/3 de los pacientes.


Acute myocarditis (AM) is associated with viral infections: Coxsackie and ECHOviruses among others. Autoimmunity has been proposed as a pathogenic mechanism. Benefit of classic immunosuppression (prednisone-azathioprine) or immunomodulation (monomeric-human IgG) is still uncertain. Objective: To review incidence and clinical approach to AM at a Cardiology referral center. Material and methods: A 10-yeard period (1992-2003) is reviewed. A standard ques-tionary was applied to 49 consecutive patients referred by clinicians with a diagnosis of AM. Results: AM was found in 17 women and 32 men, median age 24 and 28 years, respectively. They presented heart failure with dyspnea/ortop-nea (70-47%), peripheral edema/jugular vein plethora (41-37%), chest pain, and tachycardia (50%), NYHA functional class was III-IV in 22. The EKG showed sinus tachycardia or conduction defects. Transthoracic echocardiograms in 47 cases showed EF (mean) of 41% with enlarged left ventricle diameter. Antivirus antibodies were present in 54% of those cases studied, Coxsackie or ECHOvirus were identified through a serologic assay. Twenty-nine (61%) of our cases developed dilated cardiomyopathy, three patients died. It is not possible to reach a conclusion regard to immunomodulation therapy, because it was applied to only 12 patients. Conclusions: At the Instituto Nacional de Cardiología "I. Chávez", AM depicts an incidence of 1/1,000 patients a year. It is necessary to standardize the clinical approach for diagnosis and treatment, progression to dilated cardiomyopathy and deadth during acute stage occurs in two-thirds of our patients.


Subject(s)
Adult , Female , Humans , Male , Myocarditis , Acute Disease , Incidence , Myocarditis/diagnosis , Myocarditis/drug therapy , Myocarditis/epidemiology , Retrospective Studies , Time Factors
15.
Mem. Inst. Oswaldo Cruz ; 100(supl.1): 93-96, Mar. 2005.
Article in English | LILACS | ID: lil-402181

ABSTRACT

The comprehension of the pathogenesis of Trypanosoma cruzi-elicited myocarditis is crucial to delineate new therapeutic strategies aiming to ameliorate the inflammation that leads to heart dysfunction, without hampering parasite control. The augmented expression of CCL5/RANTES and CCL3/MIP-1alpha, and their receptor CCR5, in the heart of T. cruzi-infected mice suggests a role for CC-chemokines and their receptors in the pathogenesis of T. cruzi-elicited myocarditis. Herein, we discuss our recent results using a CC-chemokine receptor inhibitor (Met-RANTES), showing the participation of CC-chemokines in T. cruzi infection and unraveling CC-chemokine receptors as an attractive therapeutic target for further evaluation in Chagas disease.


Subject(s)
Animals , Mice , Chagas Cardiomyopathy/drug therapy , /analogs & derivatives , Chemokines, CC/metabolism , Myocarditis/drug therapy , Receptors, Chemokine/antagonists & inhibitors , Trypanosoma cruzi , /immunology , /immunology , Chagas Cardiomyopathy/immunology , Chagas Cardiomyopathy/metabolism , /therapeutic use , Chemotaxis, Leukocyte/immunology , Myocarditis/immunology , Myocarditis/metabolism , Myocarditis/parasitology , Trypanosoma cruzi/immunology
16.
Arq. bras. cardiol ; 84(2): 167-169, fev. 2005.
Article in Portuguese | LILACS | ID: lil-393676

ABSTRACT

Mulher de 60 anos com quadro de insuficiência cardíaca classe funcional III/IV (NYHA) de etiologia imuno-mediada (miocardite autoimune). Após tentativas terapêuticas sem sucesso, foi utilizada imunoglobulina intravenosa, deteriorando a função renal, complicação rara desta terapia. Após hemodiálise a paciente recuperou a função renal e ocorreu melhora da insuficiência cardíaca crônica para classe funcional I.


Subject(s)
Female , Humans , Middle Aged , Acute Kidney Injury , Immunoglobulins, Intravenous/adverse effects , Myocarditis/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Severity of Illness Index
17.
Indian J Pediatr ; 2002 Jun; 69(6): 513-6
Article in English | IMSEAR | ID: sea-78819

ABSTRACT

Rheumatic fever and rheumatic heart disease continue unabated in most of the developing nations, affecting young individuals. Focal outbreaks of smaller magnitude have also been reported since mid 1980s from industrialized western nations, where this disease had almost disappeared. Introduction of penicillin in mid 1940s had markedly changed the natural history of rheumatic fever, although the incidence of rheumatic fever declined in developed nations before that, due to better living conditions. Treatment of rheumatic fever chiefly involves use of antibiotics (penicillin) to eradicate streptococci, and anti-inflammatory drugs like salicylates or corticosteroids. Patients with severe carditis, congestive heart failure and/or pericarditis are best treated with corticosteroids as these are more potent anti-inflammatory agents than salicylates. Salicylates may be sufficient for cases with mild or no carditis. The treatment must be continued for 12 weeks. Several studies have shown that valvular regurgitation, and not myocarditis, is the cause of congestive heart failure in active rheumatic carditis. Therefore surgery with mitral valve replacement or repair is indicated in cases with intractable hemodynamics due to mitral regurgitation. Development of chronic valvular lesion after an episode of rheumatic fever is dependent upon presence or absence of carditis in the previous attack and compliance with secondary prophylaxis. Recurrences due to inadequate penicillin prophylaxis are responsible for hemodynamically significant chronic valvular lesions requiring surgery.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Humans , Myocarditis/drug therapy , Rheumatic Heart Disease/drug therapy , Salicylates/therapeutic use
18.
LMJ-Lebanese Medical Journal. 2001; 49 (6): 311-315
in French | IMEMR | ID: emr-57557

ABSTRACT

To determine and to evaluate valvular involvement, in particular subclinical, as confirmed by colored Doppler echocardiography [CDE] during an initial attack of acute rheumatic fever [ARF]. Means of diagnosis and therapeutic implications. materials and methods Over a 7-year period, from January 1994 to December 2000, 49 patients [27 females and 22 males], with a mean age of 9.2 years [range 5-14 years], who presented with a first attack of ARF, were diagnosed on the basis of clinical data [history, physical findings, specific laboratory data, EKG, and CDE] to determine the major and minor criteria of acute rheumatic fever. All patients were reinvestigated and controlled clinically and by echocardiography two weeks to three months after the first investigation.results Reported clinical major criteria were Arthritis, 46 cases [94%]; carditis, 27 cases [55%]; erythema marginatum, 3 cases [6%]; subcutaneous nodules, 3 cases [6%] and chorea, 3 cases [6%].CDE abnormalities were identified in 37 cases with cardiac involvement [75% of patients], 10 of them had subclinical evidence of valvular involvement 6 cases with mild to moderate mitral regurgitation [MR], 2 cases with moderate aortic regurgitation [AR], and 2 cases had both mild to moderate MR and moderate AR. All patients with subclinical disease and evidence of inflammatory process [7 cases] were treated by salicylates. Repeated echocardiography for control showed disappearance of valvular insufficiency in 8 patients with subclinical valvulopathy, and aggravation was observed in 2 other patients.conclusion CDE is recommended in patients with suspicion of ARF, even in normal cardiac auscultation in order to detect an acute cardiac involvement leading to an early diagnosis. The confirmation of subclinical valvular disease should be considered as major criteria for ARF. Isolated and subclinical mitral and/or aortic regurgitations, with evidence of inflammatory process, should, receive corticosteroids and be followed-up regularly, clinically and non-invasively by CDE


Subject(s)
Humans , Male , Female , Rheumatic Fever/diagnosis , Rheumatic Heart Disease , Echocardiography, Doppler, Color , Acute Disease , Myocarditis/drug therapy
19.
Arq. bras. cardiol ; 72(5): 601-6, maio 1999.
Article in Portuguese, English | LILACS | ID: lil-242079

ABSTRACT

Purpose - To report the result of patients treated with IV methylprednisolone divided into three groups and compare their follow-up during the last 12 years. Methods - Seventy children with active rheumatic carditis (76 episodes) in heart failure Class III and IV (NYHA) were studied. The diagnosis was based on modified Jones' criteria. After rulling out infections and stronglyoidiasis, treatment with IV methylprednisolone bolus was started three times a week until the laboratory tests became negative. Patients were divided into 3 groups, according to the time of hospital admittance: Groups 1,2 and 3, comprising of 40, 18 and 12 children, respectively. Results - Eighteen children in Group 1 (45 per cent) were in their 1st attack: 2 series of pulsetherapy were used in 10 (25 per cent), 3 in 9 (23 per cent) and 4 in 21 (52 per cent). In Group 2, 14 cases (77 per cent) were in their 1st attack: 2 series were used in 7 (39 per cent), 4 in 9 (50 per cent) and 5 in 2 (11 per cent). The echocardiogram showed a flail mitral valve in 12 (66 per cent) of these patients (1 death occurred after mitral valvoplasty). In Group 3,6 patients needed 5 or more series of pulsetherapy and a flail mitral valve was present in 5 (41 per cent). One child underwent mitral valve replacement while still in the active phase, after 8 series of pulsetherapy, and another died. The number of patients who needed 5 or more series was significantly higher in Group 3. Conclusion - There were variations in the presentation and evolution of the cases during these 12 year. The established pulsetherapy protocol continues to be useful to treat severe cases.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Anti-Inflammatory Agents/therapeutic use , Methylprednisolone/therapeutic use , Myocarditis/drug therapy , Rheumatic Heart Disease/drug therapy , Injections, Intravenous , Prospective Studies , Treatment Outcome
20.
Damascus University Journal for Health Sciences. 1998; 14 (2): 27-48
in Arabic | IMEMR | ID: emr-47836

ABSTRACT

This study was performed in Children's Hospital of Damascus University during a period of 4 years from 1/1/1993. 270 patients with myocarditis aging up to five years were studied. The most common signs were tachypnea 88.9%, retraction 67.8%, feeding refusal and cyanosis 55.9%, diminished heart sounds 51.8%, tachycardia 48.1%, flattening of T wave and depressed ST segment 85.2%, cardiomegaly on X ray 74.8%, elevation of myocardial enzymes especially LDH 94.75%, the ratio of GOT/GPT was more than one in 83.2%. 84.5% of cases were younger than 1 year of age, and 61.1% were males. The rural cases were 49.6% in contrast to urban cases 32.2%, and in winter and summer seasons more than spring and autumn. The most frequent complication was dilated myocardiopathy [35.9%]. Generally the mortality rate was 48.8%; and 89.4% of this occurred in infants younger than 1 year of age, who mostly had a preceding upper risparatory tract infection. The treatment was symptomatic; it was noticed, that the mortality rate was little less in who received steroids 38.63% in comparison to those who haven't received it 40.14%. The use of captopril in treatment of heart failure associated with cardiomyoathy was effective in improvement of heart failure


Subject(s)
Humans , Male , Female , Myocarditis/drug therapy , Infant , Child, Preschool , Captopril
SELECTION OF CITATIONS
SEARCH DETAIL